JP5406197B2 - ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法 - Google Patents

ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法 Download PDF

Info

Publication number
JP5406197B2
JP5406197B2 JP2010528917A JP2010528917A JP5406197B2 JP 5406197 B2 JP5406197 B2 JP 5406197B2 JP 2010528917 A JP2010528917 A JP 2010528917A JP 2010528917 A JP2010528917 A JP 2010528917A JP 5406197 B2 JP5406197 B2 JP 5406197B2
Authority
JP
Japan
Prior art keywords
solution
dantrolene sodium
lyophilized
dantrolene
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010528917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500570A (ja
JP2011500570A5 (Direct
Inventor
マルカウィ，アーマッド
アル−ガナニーム，アビール，エム．
デルーカ，パトリック
ディジェニス，ジョージ，エー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Us Worldmeds LLC
Original Assignee
Us Worldmeds LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Worldmeds LLC filed Critical Us Worldmeds LLC
Publication of JP2011500570A publication Critical patent/JP2011500570A/ja
Publication of JP2011500570A5 publication Critical patent/JP2011500570A5/ja
Application granted granted Critical
Publication of JP5406197B2 publication Critical patent/JP5406197B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2010528917A 2007-10-09 2008-09-05 ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法 Active JP5406197B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97862607P 2007-10-09 2007-10-09
US60/978,626 2007-10-09
PCT/US2008/075406 WO2009048698A1 (en) 2007-10-09 2008-09-05 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents

Publications (3)

Publication Number Publication Date
JP2011500570A JP2011500570A (ja) 2011-01-06
JP2011500570A5 JP2011500570A5 (Direct) 2011-02-17
JP5406197B2 true JP5406197B2 (ja) 2014-02-05

Family

ID=40316940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010528917A Active JP5406197B2 (ja) 2007-10-09 2008-09-05 ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法

Country Status (6)

Country Link
US (1) US8975284B2 (Direct)
EP (2) EP2219605B1 (Direct)
JP (1) JP5406197B2 (Direct)
CA (1) CA2702243C (Direct)
ES (1) ES2583804T3 (Direct)
WO (1) WO2009048698A1 (Direct)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080098614A1 (en) * 2006-10-03 2008-05-01 Wyeth Lyophilization methods and apparatuses
WO2009067175A2 (en) 2007-11-16 2009-05-28 Nektar Therapeutics Al, Corporation Oligomer-dantrolene conjugates and related compounds
US20120040970A1 (en) * 2009-04-27 2012-02-16 Al-Ghananeem Abeer M Intranasal delivery system for dantrolene
US20140072525A1 (en) * 2012-09-07 2014-03-13 Gaab, Llc Antimicrobial preparation and methods for making and using the same
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
JP2016514685A (ja) * 2013-03-15 2016-05-23 ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス 異常レベルのカルシウム放出からリアノジン受容体を安定化するための化合物
WO2015157212A1 (en) * 2014-04-10 2015-10-15 Us Worldmeds, Llc Stable apomorphine composition and uses thereof
PL3364947T3 (pl) * 2015-10-20 2022-02-07 B. Braun Melsungen Ag Wodna kompozycja zawierająca dantrolen
CA3067457A1 (en) * 2017-06-20 2018-12-27 Tarveda Therapeutics, Inc. Targeted therapeutics
SG11202003452XA (en) 2017-10-20 2020-05-28 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
WO2019175761A1 (en) * 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions
TW202011940A (zh) * 2018-04-05 2020-04-01 美商塔維達治療公司 具有降低量的三級丁醇之藥學組成物
JPWO2020049670A1 (ja) * 2018-09-06 2021-08-12 シミックホールディングス株式会社 ダントロレン水性製剤及びその調製方法
WO2020112932A1 (en) * 2018-11-27 2020-06-04 Eagle Pharmaceuticals, Inc. Use of dantrolene and dantrolene prodrugs to treat radiation exposure
WO2022169582A1 (en) * 2021-02-05 2022-08-11 Uswm, Llc Compositions and methods for clear concentrated parenteral delivery of dantrolene therapeutic agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415821A (en) * 1965-09-07 1968-12-10 Norwich Pharma Co 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones
US4543359A (en) 1982-10-01 1985-09-24 Eaton Laboratories, Inc. Treating cardiac arrhythmias with dantrolene sodium
US5145769A (en) 1987-08-21 1992-09-08 Cryolife Inc. Method for cryopreserving blood vessels
US5149621A (en) * 1987-08-21 1992-09-22 Cryolife, Inc. & Medical Univ. Of South Carolina Kit for cryopreserving blood vessels
US5158867A (en) 1987-08-21 1992-10-27 Cryolife Inc. Method for cryopreserving blood vessels
JPH01128923A (ja) * 1987-11-11 1989-05-22 Mikasa Seiyaku Kk 骨格筋弛緩外用剤
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
WO1994005287A1 (en) * 1992-09-09 1994-03-17 Washington University Prevention or treatment of sepsis with dantrolene or azumolene
JPH06263636A (ja) * 1993-03-12 1994-09-20 Kiyoshi Kataoka 脳または高次神経疾患治療剤
DE69528165T2 (de) 1994-04-21 2003-05-15 Hisamitsu Pharmaceutical Co., Inc. Transdermal verabreichbare grundlage und daraus hergestelltes transdermal verabreichbares arzneimittel
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US7758890B2 (en) * 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
EP1435781A4 (en) * 2001-06-23 2007-06-20 Lyotropic Therapeutics Llc SOLVENT SYSTEM
SI1603513T1 (sl) * 2003-03-04 2021-04-30 Lyotropic Therapeutics, Inc. Sestavki dantrolena
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR072777A1 (es) * 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina

Also Published As

Publication number Publication date
WO2009048698A9 (en) 2009-11-19
JP2011500570A (ja) 2011-01-06
WO2009048698A1 (en) 2009-04-16
ES2583804T3 (es) 2016-09-22
EP2219605B1 (en) 2015-08-19
CA2702243A1 (en) 2009-04-16
EP2219605A1 (en) 2010-08-25
CA2702243C (en) 2016-06-21
US8975284B2 (en) 2015-03-10
EP2583670A1 (en) 2013-04-24
US20090093531A1 (en) 2009-04-09
WO2009048698A4 (en) 2013-05-30
US20110015243A2 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
JP2011500570A (ja) ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法
US20110160261A2 (en) Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
JP2022116191A (ja) 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
EP3505161B1 (en) Sublingual pharmaceutical composition of edaravone and (+)-2-borneol
JP6461945B2 (ja) ある含有量のマイトマイシンｃを有する凍結乾燥医薬組成物を製造する方法
US20140142153A1 (en) Bendamustine formulations
JP6182262B2 (ja) 抗がん剤を含む安定な水溶性医薬組成物
JP2012167132A (ja) Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物の凍結乾燥製剤
CN103202815A (zh) 治疗精神疾病的注射剂
JPH11507936A (ja) ラモトリジン含有医薬組成物
KR101468153B1 (ko) 5α-안드로스테인-3β,5,6β-트리올 주사제 및 제조방법
KR20010034552A (ko) 포스포리파제 저해제인 소듐[[3-(2-아미노-1,2-디옥소에틸)-2-에틸-1-(페닐메틸)-1ｈ-인돌-4-일]옥시]아세테이트를 포함하는 약학적 조성물
CN102342931B (zh) 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法
CN111848512A (zh) 使用高纯度盐酸罂粟碱制备粉针剂药物组合物
WO2025113679A1 (zh) 药物组合物、制剂、美托拉宗冻干粉制剂及其制备方法与用途
JPWO2002007724A1 (ja) Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物の凍結乾燥製剤およびその製造方法
WO2024170010A1 (zh) 一种注射用依维莫司缓释微球及其制备方法
CN111789818B (zh) 注射用盐酸罂粟碱药物组合物及制备方法
WO2017198224A1 (zh) 一种瑞马唑仑的药物组合物
CN102552140B (zh) 罗格列酮的液体组合物
CN106963768A (zh) 一种药物组合物及用途
CN110693882A (zh) 一种舌下用药物组合物
KR20160090312A (ko) 조산 조건의 치료에서 사용을 위한 용량 단위의 조합
WO2022169582A1 (en) Compositions and methods for clear concentrated parenteral delivery of dantrolene therapeutic agents
JP2023516957A (ja) ダプトマイシン製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130909

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131031

R150 Certificate of patent or registration of utility model

Ref document number: 5406197

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250